Cite Filings / ABUS / 0001140361-25-005025
Feed Companies Filings Check
Sign in
Cite Filings

Pages

  • Feed
  • Companies
  • Filings
  • Check a claim

Account

  • Sign in
  • Create an account
Support (opens in new tab)
SCHEDULE 13D/A

Beneficial Ownership Report

Arbutus Biopharma Corp · Filed 2025-02-18 · Acc 0001140361-25-005025

Documents 1

  • SCHEDULE 13D/A Beneficial Ownership Report , xslSCHEDULE_13D_X01/primary_doc.xml

Around this filing

  • 2025-02-25 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-02-21 SCHEDULE 13D/A Beneficial Ownership Report
  • 2025-02-19 4 General Counsel and CCO acquired 54,300 shares (grant or award)
  • 2025-02-19 4 Interim President & CEO acquired 177,000 shares (grant or award)
  • 2025-02-19 4 Chief Financial Officer acquired 90,100 shares (grant or award)
  • 2025-02-19 4 Chief Medical Officer acquired 49,300 shares (grant or award)
  • 2025-02-18 SCHEDULE 13D/A Beneficial Ownership Report

Link to a passage

At least 12 characters, not counting spaces, so the link points to one passage.

External

  • SEC EDGAR (opens in new tab)

Stakes reported in this filing

Stake history · largest stake in each 13D and 13G

  1. 2026-11-16 SCHEDULE 13G/A · Two Seas Capital LP 4.1%
  2. 2026-11-16 SCHEDULE 13G/A · Whitefort Capital Master Fund, LP 1.6%
  3. 2026-11-16 SCHEDULE 13G · NOMURA HOLDINGS INC 7.3%
  4. 2026-10-05 SCHEDULE 13D/A · Roivant Sciences Ltd. 19.5%
Loading xslSCHEDULE_13D_X01/primary_doc.xml…

Connection lost

Reconnecting…

Cite Filings isn't responding

Reconnecting…